Fig. 6.
68Ga-DOTA-TATE-PET/CTs in a patient with metastatic neuroendocrine tumor before (top row) and after (bottom row) radionuclide therapy with 177Lu-DOTA-TATE. The pre-treatment diagnostic scan showed multiple avid liver metastases (arrows), implying that they would also bind the 177Lu-labelled therapeutic ‘sister agent’, therefore predicting the treatment response that was ultimately demonstrated on the post-therapeutic PET/CT. Physiologic splenic tracer uptake is seen on both studies